Deal of the Year

Allicense 2014 Breakthrough Awards

The Breakthrough Awards was presented at the Allicense conference on April 29th, 2014. This annual award honors the creative partnering efforts of business development licensing and M&A professionals. Thomson Reuters deals analysts examined hundreds of biopharma licensing and M&A deals negotiated across 2013 and use both subjective and objective criteria, to identify the top five contenders for deal of the year across categories: Licensing and M&A. Congratulations to ISIS Pharmaceuticals and Biogen Idec, who won the award for Licensing Deal of the Year, and to Amplimmune and Medimmune, who won M&A Deal of the Year. See the press release here

This year’s award nominees are as follows:

Licensing

Pfizer (seller) / Lilly (buyer)

Date October 2013
Financials $1,780 MillionTotal Size / $200 Million Upfront
Asset tanezumb (PF-4383119), a human MAb for osteoarthritis, chronic low back pain and cancer pain. Phase III at signing. (Worldwide)
Therapeutic Area Autoimmune/Inflammatory

OncoMed Pharmaceuticals (seller) / Celgene (buyer)

Date December 2013
Financials $3,332.2 Million Total Size / $155 Million Upfront
Asset demcizumab and five biologics: an anti-DLL4/VEGF bispecific antibody and up to four other targeting CSC pathways. Phase I at signing. (Worldwide)
Therapeutic Area Cancer

Moderna Therapeutics (seller) / AstraZeneca (buyer)

Date March 2013
Financials Total Size Confidential / $240 Million Upfront
Asset mRNA therapeutics for cardiometabolic, renal, and cancer targets, discovered under a 5-year collaboration. Discovery stage at signing. (Worldwide)
Therapeutic Area Diversified

Ablynx (seller) / AbbVie (buyer)

Date September 2013
Financials $840 Million Total Size / $175 Million Upfront
Asset ALX-0061, anti-IL-6R inhibitor nanobody for rheumatoid arthritis and systematic lupus erythematosus. Phase II at signing.
Therapeutic Area Autoimmune/Inflammatory

ISIS Pharmaceuticals (seller) / Biogen Idec (buyer)

Date September 2013
Financials Total Size Confidential / $100 Million Upfront
Asset Therapies for neurological diseases using Isis’ antisense technology – Oligonucleotide Ligands and siRNAs. Discovery stage at signing.
Therapeutic Area Neurology

M&A

Aragon Pharmaceuticals (seller) / Johnson & Johnson (buyer)

Date Closed August 2013
Financials $1,000 MillionTotal Size / $650 Million Upfront
Leading Products ARN-509, ARN-810; ARN-912
Most Advanced Product Phase II
Therapeutic Area Cancer

Amplimmune, Inc (seller) / Medimmune (AstraZeneca) (buyer)

Date Closed August 2013
Financials $500 Million Total Size / $225 Million Upfront
Leading Products AMP-224, AMP-110, AMP-514
Most Advanced Product Preclinical
Therapeutic Area Cancer

Okairos AG (seller) / GlaxoSmithKline (buyer)

Date Closed November 2013
Financials $420 Million Total Size / $325 Million Upfront
Leading Products ProCvax, TerCvax
Most Advanced Product Phase II
Therapeutic Area Infectious Disease

Lotus Tissue Repair (seller) / Shire (buyer)

Date Closed December 2013
Financials $324.3 Million Total Size / $49.3 Million Upfront
Leading Products Recombinant collagen Type VII (rC7)
Most Advanced Product Preclinical
Therapeutic Area Dermatologic

Trius Therapeutics (seller) / Cubist Pharmaceuticals (buyer)

Date Closed November 2013
Financials $818 Million Total Size / $707 Million Upfront
Leading Products TR-701, GyrB/ParE
Most Advanced Product Phase III
Therapeutic Area Infectious Disease

Download the full nominee announcement slide deck for more details here.

Twitter
LinkedIn
Blog

Join the conversation on Twitter: #Allicense2014

Syndax